AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NRIX

Ring Christine sold $134K of NRIX

Ring Christine (Chief Legal Officer) sold 5,786 shares of Nurix Therapeutics, Inc. (NRIX) at $23.19 ($0.13M total) on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ring Christine
Published Oct 2, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
medium confidence
Mentioned
$NRIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it provides transparency for investors monitoring insider behavior.

02

Market read

A routine insider sale with limited material impact; useful for compliance monitoring but low trading relevance.

03

What to watch

The insider's remaining stake remains sizable; no change in control or strategic direction.

Relevance 3/10Novelty 3/10Timing: same day filing

Background

Form 4 filing discloses insider transactions required by the SEC; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$NRIXNeutralMedium confidence
Context

Chief Legal Officer sold 5,786 shares for $134,149 via a 10b5-1 plan, reducing her stake to 9,110 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

C-level insider sale of $134k is modest; investors may view it as routine, limiting price effect.

Market effects

Sector

Minimal impact on the biotech sector; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and may be a portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Nurix Therapeutics, Inc.

    Biopharma company developing targeted protein degradation therapies.

  • Person
    Ring Christine

    Chief Legal Officer of Nurix Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

tradingview.com
$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

genengnews.com
$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

investing.com